Central nervous system remyelination in culture - A tool for multiple sclerosis research

被引:100
|
作者
Zhang, Hui [1 ]
Jarjour, Andrew A. [1 ]
Boyd, Amanda [1 ]
Williams, Anna [1 ]
机构
[1] Univ Edinburgh, Queens Med Res Ctr, MS Ctr, Ctr Regenerat Med, Edinburgh EH16 4TJ, Midlothian, Scotland
基金
英国惠康基金;
关键词
Remyelination; Multiple sclerosis; Oligodendrocyte; Myelination; Demyelination; CNS DEMYELINATION; SLICE CULTURES; MYELINATION; OLIGODENDROCYTES; LESIONS; DISABILITY; MODELS; TISSUE; DAMAGE; CELLS;
D O I
10.1016/j.expneurol.2011.04.009
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Multiple sclerosis is a demyelinating disease of the central nervous system which only affects humans. This makes it difficult to study at a molecular level, and to develop and test potential therapies that may change the course of the disease. The development of therapies to promote remyelination in multiple sclerosis is a key research aim, to both aid restoration of electrical impulse conduction in nerves and provide neuroprotection, reducing disability in patients. Testing a remyelination therapy in the many and various in vivo models of multiple sclerosis is expensive in terms of time, animals and money. We report the development and characterisation of an ex vivo slice culture system using mouse brain and spinal cord, allowing investigation of myelination, demyelination and remyelination, which can be used as an initial reliable screen to select the most promising remyelination strategies. We have automated the quantification of myelin to provide a high content and moderately-high-throughput screen for testing therapies for remyelination both by endogenous and exogenous means and as an invaluable way of studying the biology of remyelination. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:138 / 148
页数:11
相关论文
共 50 条
  • [21] Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis
    Cadenas-Fernandez, Jennifer
    Ahumada-Pascual, Pablo
    Andreu, Luis Sanz
    Velasco, Ana
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (30) : 3273 - 3280
  • [22] Remyelination Therapy for Multiple Sclerosis
    Keough, Michael B.
    Yong, V. Wee
    NEUROTHERAPEUTICS, 2013, 10 (01) : 44 - 54
  • [23] Monocytes in central nervous system remyelination
    Forbes, Lindsey H.
    Miron, Veronique E.
    GLIA, 2022, 70 (05) : 797 - 807
  • [24] GABAB receptor agonist baclofen promotes central nervous system remyelination
    Paz Serrano-Regal, Mari
    Bayon-Cordero, Laura
    Chara Ventura, Juan Carlos
    Ochoa-Bueno, Blanca, I
    Tepavcevic, Vanja
    Matute, Carlos
    Victoria Sanchez-Gomez, Maria
    GLIA, 2022, 70 (12) : 2426 - 2440
  • [25] Transplantation options for therapeutic central nervous system remyelination
    Blakemore, WF
    Franklin, RJM
    CELL TRANSPLANTATION, 2000, 9 (02) : 289 - 294
  • [26] Glial cell transplantation and remyelination of the central nervous system
    Duncan, ID
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1996, 22 (02) : 87 - 100
  • [27] CENTRAL-NERVOUS-SYSTEM DEMYELINATION AND REMYELINATION IN MULTIPLE-SCLEROSIS AND VIRAL MODELS OF DISEASE
    RODRIGUEZ, M
    JOURNAL OF NEUROIMMUNOLOGY, 1992, 40 (2-3) : 255 - 264
  • [28] Myelin regulatory factor drives remyelination in multiple sclerosis
    Duncan, Greg J.
    Plemel, Jason R.
    Assinck, Peggy
    Manesh, Sohrab B.
    Muir, Fraser G. W.
    Hirata, Ryan
    Berson, Matan
    Liu, Jie
    Wegner, Michael
    Emery, Ben
    Moore, G. R. Wayne
    Tetzlaff, Wolfram
    ACTA NEUROPATHOLOGICA, 2017, 134 (03) : 403 - 422
  • [29] Remyelination in multiple sclerosis
    Brück, W
    Kuhlmann, T
    Stadelmann, C
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) : 181 - 185
  • [30] Impaired remyelination in late-onset multiple sclerosis
    Stork, Lidia
    Stephan, Schirin
    Kutllovci, Adriane
    Brueck, Wolfgang
    Metz, Imke
    ACTA NEUROPATHOLOGICA, 2025, 149 (01)